For research use only. Not for therapeutic Use.
Taletrectinib（Cat No.:I014970）is a selective, potent inhibitor of tropomyosin receptor kinase (TRK) fusion proteins, which are associated with various cancers. TRK fusions, often occurring in solid tumors like lung cancer, lead to uncontrolled cell growth. By targeting TRK, taletrectinib blocks the downstream signaling pathways that drive tumor progression, making it an effective treatment for cancers with TRK fusions. The free base form of taletrectinib is used in research and clinical development. Clinical trials have shown promising results, particularly in patients with TRK fusion-positive cancers, making it a potential targeted therapy for these malignancies.
| Catalog Number | I014970 |
| CAS Number | 1505514-27-1 |
| Molecular Formula | C₂₃H₂₄FN₅O |
| Purity | ≥95% |
| Target | ROS Kinase |
| IUPAC Name | 3-[4-[(2R)-2-aminopropoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine |
| InChI | InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)/t15-,16-/m1/s1 |
| InChIKey | HEVHTYMYEMEBPX-HZPDHXFCSA-N |
| SMILES | C[C@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N |
| Reference | [1]. Katayama R, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604. Published 2019 Aug 9.<br>[2]. Fujiwara Y, et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018;9(34):23729-23737. Published 2018 May 4. |
